Direct Medical Care Costs Associated With Patients Diagnosed With Chronic HCV

Authors Information
Article Notes and Dates
To Cite : Ashtari S, Vahedi M, Pourhoseingholi M A, Karkhane M, Kimiia Z, et al. Direct Medical Care Costs Associated With Patients Diagnosed With Chronic HCV, Hepat Mon. 2013 ;13(5):e8415. doi: 10.5812/hepatmon.8415.
Copyright: Copyright © 2013, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
Abstract
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Alavian SM. We need a new national approach to control hepatitis C: It is becoming too late. Hepat Mon. 2008; 8(3): 165-9[PubMed]
  • 2. Alavian SM. Hepatitis C infection in Iran; A review article. Iran J Clin Infect Dis. 2009; 4(1): 47-59
  • 3. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007; 13(17): 2436-41[PubMed]
  • 4. Brown RSJr, Gaglio PJ. Scope of worldwide hepatitis C problem. Liver Transpl. 2003; 9(11)-3[PubMed]
  • 5. Alavian SM, Lankarani KB, Alaei-Andabili SH, Pouryasin A, Ebrahimi Daryani N, Nassiri Toosi M, et al. Treatment of chronic hepatitis C Infection: Updated of the Recommendation from Scientific Leaders' Meeting-28th July 2011-tehran, IR iRAN. Hepat Mon. 2011; 11(9): 703-13
  • 6. Alavian SM, Ahmadzad Asl M, Lankarani KB, Shahbabaie MA, Bahrami Ahmadi A, Kabir A. Hepatitis C Infection in the General Population of Iran: A Systematic Review. Hepat Mon. 2009; 9(3): 211-23
  • 7. Merat S, Rezvan H, Nouraie M, Jafari E, Abolghasemi H, Radmard AR, et al. Seroprevalence of hepatitis C virus: the first population-based study from Iran. Int J Infect Dis. 2010; 14 Suppl 3-6[PubMed]
  • 8. Alavian SM, Adibi P, Zali MR. Hepatitis C virus in Iran: Epidemiology of an emerging infection. Arch Iran Med. 2005; 8(2): 84-90
  • 9. Williams R. Global challenges in liver disease. Hepatology. 2006; 44(3): 521-6[PubMed]
  • 10. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology. 1997; 26(3): 34S-8S[PubMed]
  • 11. El Saadany S, Coyle D, Giulivi A, Afzal M. Economic burden of hepatitis C in Canada and the potential impact of prevention. Results from a disease model. Eur J Health Econ. 2005; 6(2): 159-65[PubMed]
  • 12. Alavian SM. Hepatitis C virus infection: Epidemiology, risk factors and prevention strategies in public health in I.R. IRAN. Gastro Hepat. 2010; 3(1): 5-14
  • 13. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009; 29 Suppl 1: 74-81[PubMed]
  • 14. Kanwal F, Farid M, Martin P, Chen G, Gralnek IM, Dulai GS, et al. Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis. Am J Gastroenterol. 2006; 101(9): 2076-89[PubMed]
  • 15. Leigh JP, Bowlus CL, Leistikow BN, Schenker M. Costs of hepatitis C. Arch Intern Med. 2001; 161(18): 2231-7[PubMed]
  • 16. Dienstag JL, Isselbacher KJ. Harrison's principles of internal medicine. 2005;
  • 17. Kenneth W, Lin MD, Jeffrey T, Kirchner DO. Lancaster, American Family Physicisn. Pennsylvania. 2004; 69: 75-82
  • 18. Rice DP. Cost of illness studies: what is good about them? Inj Pre. 2000; 6(3): 175-6
  • 19. Berenguer J, Alvarez-Pellicer J, Martin PM, Lopez-Aldeguer J, Von-Wichmann MA, Quereda C, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology. 2009; 50(2): 407-13[PubMed]
  • 20. Singal AK, Singh A, Jaganmohan S, Guturu P, Mummadi R, Kuo YF, et al. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol. 2010; 8(2): 192-9[PubMed]
  • 21. Ahmadipour MH, Alavian SM, Amini S, Azadmanesh K. Hepatitis C Virus Genotypes. Hepat Mon. 2003; 5(3): 77-82
  • 22. Coppola N, Pisaturo M, Tonziello G, Sagnelli C, Sagnelli E, Angelillo IF. Efficacy of pegylated interferon alpha-2a AND alpha-2b in patients with genotype 1 chronic Hepatitis C: a meta-analysis. BMC Infect Dis. 2012; 12(1): 357[PubMed]
  • 23. Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J. Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology. 2000; 31(1): 211-8[PubMed]
  • 24. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet. 2003; 362(9401): 2095-100[PubMed]
  • 25. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347(13): 975-82[PubMed]
  • 26. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004; 39(4): 1147-71[PubMed]
  • 27. Center for Disease Control and Prevention. Cost analysis: Introduction/CDC Econ Eval Tutorials.
  • 28. Moghimi-Dehkordi B, Vahedi M, Khoshkrood Mansoori B, Kasaeian A, Safaee A, Habibi M, et al. Economic burden of gastro-oesophageal reflux disease and dyspepsia: A community-based study. Arab J Gastroenterol. 2011; 12(2): 86-9[PubMed]
  • 29. Moghimi-Dehkordi B, Vahedi M, Pourhoseingholi MA, Khoshkrood Mansoori B, Safaee A, Habibi M, et al. Economic burden attributable to functional bowel disorders in Iran: a cross-sectional population-based study. J Dig Dis. 2011; 12(5): 384-92[PubMed]
  • 30. Mohaghegh Shalmani H, Soori H, Khoshkrood Mansoori B, Vahedi M, Moghimi-Dehkordi B, Pourhoseingholi MA, et al. Direct and indirect medical costs of functional constipation: a population-based study. Int J Colorectal Dis. 2011; 26(4): 515-22[PubMed]
  • 31. Roshandel D, Rezailashkajani M, Shafaee S, Zali MR. A cost analysis of functional bowel disorders in Iran. Int J Colorectal Dis. 2007; 22(7): 791-9[PubMed]
  • 32. Medical Laws and Tariffs. [The price list by Iranian Cabinet of the Public Health Centers]. 2010;
  • 33. Iranian Ministry of Health and Medical Education. [List of price of drugs]. 2010;
  • 34. Trading Economic Website. 2010;
  • 35. Amini S, Abadi MMFM, Alavian SM, Joulaie M, Ahmadipour MH. Distribution of Hepatitis C Virus Genotypes in Iran: A Population-Based Study. Hepat Mon. 2009; 9(2): 95-102[PubMed]
  • 36. Palumbo E. Pegylated interferon and ribavirin treatment for hepatitis C virus infection. Ther Adv Chronic Dis. 2011; 2(1): 39-45[PubMed]
  • 37. Iranian Databases of Census Publication. 2006;
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiaion Alert via Google Reader

Cited By:

Hepatitis Monthly accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check